Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | STS | P08842 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30879864 | 0.90 | NPSR1 (0.64) | TACR1ALDH1A1USP2HPGDNPSR1 | |
| SCHEMBL27309928 | 0.90 | NPSR1 (0.64) | TACR1ALDH1A1USP2HPGDNPSR1 | |
| SCHEMBL12804554 | 0.89 | NPSR1 (0.68) | ALDH1A1USP2HPGDNPSR1STS | |
| SCHEMBL17476822 | 0.89 | KMT2A (0.56) | TACR1ALDH1A1USP2LMNASMN1; SMN2 | |
| SCHEMBL22617001 | 0.88 | GAA (0.67) | TACR1ALDH1A1USP2HPGDNPSR1 | |
| SCHEMBL22616979 | 0.88 | GAA (0.67) | TACR1ALDH1A1USP2HPGDNPSR1 | |
| SCHEMBL20116390 | 0.88 | TACR1 (0.54) | TACR1ALDH1A1USP2HPGDNPSR1 | |
| SCHEMBL17013356 | 0.86 | TACR1 (0.51) | TACR1ALDH1A1USP2HPGDNPSR1 | |
| SCHEMBL23951479 | 0.83 | TACR1 (0.78) | TACR1ALDH1A1STSLMNANAMPT | |
| SCHEMBL42425 | 0.83 | NPC1 (0.73) | TACR1ALDH1A1NPSR1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4547247-A2 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024006956-A9 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024006956-A2 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20080275086-A1 | Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20080275086-A1 | Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20080275086-A1 | Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-11-06 | — | — | US | disclosed |
| EP-1858846-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006097175-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| EP-1702916-A1 | DPP-IV inhibitors | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2006-09-20 | — | — | EP | disclosed |
| EP-1702916-A1 | DPP-IV inhibitors | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275086-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | TACR1 736/4885ALDH1A1 715/4885USP2 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.